Injectables and implantables are key to advancing patient centricity and adherence
The development of controlled and prolonged release injectable and implantable drugs has seen huge leaps forward in recent years. Increasing prevalence of chronic diseases; innovative technological advancements; growth in complex therapies such as biologics: together these factors create the potential for drug delivery solutions which offer greater patient freedom and improved adherence. Which disease areas offer the best opportunities for injectables and implantables? And what is the current position on core issues such as reimbursement, real world evidence and regulation? Now you can find out the answers to these crucial questions and more.
- Who, what, why: Which pharma and medtech companies are making progress? What new implantable devices and novel injectable drugs have reached the market? Which therapy areas can benefit most and why?
- The finance issues: Up-front cost is not the only consideration; long-term adherence can be significantly improved with injectables or implantables use. So, what are the factors causing payer reluctance? And how should real world evidence form part of the solution?
- The regulatory issues: What is the current position regarding regulatory approval for injectables and implantables? And what local and global challenges must be overcome before proceeding?
- The patient perspective: Understand how injectables and implantables make a significant difference to patient outcomes, improve adherence, and enhance quality of life.
- The physician perspective: What more should pharma do to educate and encourage doctors to opt for injectables and implantables? Is enough being done to evidence efficacy and safety as well as patient advantages?
What to expect from this report
This report offers an up-to-date view of the fast-developing injectables and implantables market, identifying the key opportunities as well as recognising the challenges and barriers facing pharma companies looking to invest in this promising area. Delving into a wide range of issues from regulation to real world evidence to ethics and social constraints, The FutureViews Injectables and Implantables report provides the experts' view of the market to inform current and future investment strategy.
What did we do?
- We identified 8 current issues regarding injectables and implantables
- We explored these via secondary research to develop 15 targeted questions that we put to leading experts
- We used all of this to identify 30 unique new insights
- Insights are supported by 45 directly quoted comments and 60 additional source references
Example insight included in Injectables and Implantables
"If pharma is to provide access to injectables/implantables to emerging markets, it must address storage issues and social barriers. Many lower- and middle-income countries are also in regions of the world where elevated temperatures that would require cold storage for biologics. Injectables/implantables will also require aseptic facilities of manufacturing. Without adequate storage and aseptic facilities, medicines could be at risk for contamination. Additionally, manufacturers may encounter social and religious barriers to the use of some medicines such as contraceptives and vaccines: these must first be identified so that pharma can adopt storage-friendly formulations and devise culturally sensitive solutions to adoption barriers."
Example quote included in Injectables and Implantables
"Like all novel technologies entering the medical marketplace, clinician and patient adoption is indicative of a successful product. The pharma market can do a lot to help educate and provide useful information to the public regarding the benefits and patient outcomes from utilising new technologies that are entering the marketplace in the space of drug delivery. The key to knowledge is spreading awareness."
Idicula Mathew, Co-Founder & CEO, Hera Health Solutions, US
The expert panel for Injectables and Implantables
- René Holm, Head and Scientific Director of Drug Product Development – Liquids & Parenterals at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J).
- Idicula Mathew, CEO and co-founder of Hera Health Solutions, a pharmaceutical device start-up that specialises in the development and commercialisation of long-acting treatments through proprietary biodegradable drug delivery implants.
- Christopher Rhodes PhD, President, CEO and Founder of Drug Delivery Experts, a boutique drug product development firm that supports pharma and biotech companies on the research, development and translation of drug delivery systems from ideation to R&D, and on to commercialisation.
Why this report is important
Improving adherence is one of the biggest challenges facing pharma; it's also perhaps the most powerful benefit of injectables and implantables. Longer lasting medication means less frequent delivery, which in turn means fewer physician appointments and fewer lapses. More discrete administering of drugs is obviously preferable for patients. Injectables and implantables offer a way forward that is far easier and more convenient for all, and enables physicians to offer a holistic response as well as improved health outcomes.
Why FirstWord reports are different
- 100% new content: You won't find old research presented as new. Guaranteed.
- Opinions you need to hear: We only interview experts with current, relevant experience.
- Professional researchers: The knowledge, experience and contacts to get the answers you need.